Clinical significance of runt-related transcription factor 1 polymorphism in prostate cancer
Clinical significance of runt-related transcription factor 1 polymorphism in prostate cancer
复制标题
DOI：
10.1111/j.1464-410x.2010.09512.x
复制
发表时间：
2011-02-01
影响因子：
4.5
通讯作者：
Bao, Bo-Ying
中科院分区：
文献类型：
--
作者：
Huang, Shu-Pin;Lan, Yu-Hsuan;Bao, Bo-Ying
虽然大多数接受根治性前列腺切除术的临床局限性前列腺癌患者具有良好的结果，但仍迫切需要能够提供预后信息的分子标记物来识别可能受益于积极治疗的高危患者。在这项研究中，我们发现RUNX 1 rs 2253319多态性与晚期病理分期、淋巴结转移和疾病复发时间的风险显著相关。我们的研究结果表明，一个简单的和预处理分析的遗传变异可能增加预后价值，目前使用的指标，预后预测患者接受根治性前列腺切除术。目的探讨RUNX 1 rs 2253319与前列腺癌（PCa）的临床病理特征和疾病复发后根治性前列腺切除术（RP）。患者和方法利用314例接受RP治疗的局限性PCa患者队列中每个肿瘤的系统分期和分级，我们评估了RUNX 1 rs 2253319与诊断时的年龄、术前前列腺特异性抗原（PSA）水平、Gleason评分、手术切缘、病理分期、淋巴结转移状态和RP术后PSA复发。RUNX 1 rs 2253319的次要等位基因T和次要纯合子TT基因型与晚期病理分期风险增加1.49- 2.76倍和淋巴结转移风险增加3.35- 9.52倍显著相关。在Kaplan-Meier分析中，与主要纯合子CC基因型相比，RUNX 1 rs 2253319 TT基因型也与更差的无PSA生存率相关（对数秩检验，P = 0.038）和校正年龄和PSA浓度的多变量考克斯比例风险模型结论RUNX 1 rs 2253319与前列腺癌患者的临床病理特征相关，可能是前列腺癌复发的预后因素。
Although most clinically localized prostate cancer patients who underwent radical prostatectomy have a favorable outcome, molecular markers capable of providing prognostic information are still urgently needed to identify high-risk patients who might benefit from aggressive treatment. In this study, we found that RUNX1 rs2253319 polymorphism was significantly associated with higher risks of advanced pathological stage, lymph node metastasis, and time to disease recurrence. Our results suggest that a simple and pretreatment analysis of genetic variants might add prognostic value to the currently used indicators for outcome prediction in patients receiving radical prostatectomy.OBJECTIVETo investigate the association of RUNX1 rs2253319 with clinicopathological characteristics of prostate cancer (PCa) and disease recurrence after radical prostatectomy (RP).PATIENTS AND METHODSTaking advantage of the systematic stage and grade for each tumor in a cohort of 314 patients with localized PCa receiving RP, we evaluated the associations of RUNX1 rs2253319 with age at diagnosis, preoperative prostate-specific antigen (PSA) level, Gleason score, surgical margin, pathologic stage, status of lymph node metastasis, and PSA recurrence after RP.RESULTSThe minor allele, T, and the minor homozygote TT genotype of RUNX1 rs2253319 were significantly associated with a 1.49- to 2.76-fold higher risk for advanced pathologic stage and a 3.35- to 9.52-fold higher risk for lymph node metastasis. RUNX1 rs2253319 TT genotype was also associated with poorer PSA-free survival compared with the major homozygote CC genotype in Kaplan-Meier analysis (log-rank test, P = 0.038) and multivariate Cox proportional hazards model adjusting for age and PSA concentration (P = 0.045).CONCLUSIONRUNX1 rs2253319 is associated with adverse clinicopathological features and might be a prognostic factor for the recurrence of PSA in patients with PCa receiving RP.